MIAMI, Jan. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023 at the Westin St. Francis in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 11th at 4:30 p.m. Pacific time.
The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessible by clicking here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Bruce Voss, 310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.36 |
| Daily Change: | -0.06 -4.23 |
| Daily Volume: | 1,615,485 |
| Market Cap: | US$1.080B |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
